Acrux (ASX:ACR) Reports A$20M Revenue and Announces US Product Launches
Acrux (ASX:ACR) reports A$20 million revenue for FY23-FY24 and announces new US product launches, bolstering its presence in the pharmaceutical market.
Category: Healthcare
Archer Materials Limited (ASX:AXE) Enhances Biochip Feasibility and Advances Development Roadmap
Archer Materials Limited (ASX:AXE) improves Biochip’s potassium detection accuracy, advances to human blood testing, and plans regulatory engagements.
Dimerix Limited (ASX:DXB) Reports Half-Year Financial Results
Dimerix Limited (ASX:DXB) reports a 113% revenue increase in the half-year ended December 2024, alongside a 93% rise in losses.
4DMedical (ASX:4DX) Gains Regulatory Approval for CT LVAS™ in Canada
4DMedical (ASX:4DX) secures Canadian approval for CT LVAS™, expanding its respiratory imaging portfolio and market reach.
4DMedical Limited (ASX:4DX) Launches Share Purchase Plan
4DMedical Limited (ASX:4DX) launches a Share Purchase Plan, enabling shareholders to buy up to $30,000 in new shares without fees.
Telix Pharmaceuticals Limited (ASX:TLX) Changes Reporting Currency to USD
Telix Pharmaceuticals Limited (ASX:TLX) will change its reporting currency from AUD to USD effective 1 January 2025, aligning financial reports with its US-based operations.
Noxopharm Limited (ASX:NOX) Reports FY2025 Half Year Results
Noxopharm Limited (ASX:NOX) reports a 50.5% reduction in half-year losses and advances its clinical trials and strategic partnerships.
Neuren Pharmaceuticals (ASX:NEU) Receives FDA Rare Pediatric Disease Designation
Neuren Pharmaceuticals (ASX:NEU) receives FDA Rare Pediatric Disease Designation for NNZ-2591 in multiple syndromes, potentially qualifying for a priority review voucher.
PolyNovo Limited (ASX:PNV) Reports Record Half-Year Financial Results
PolyNovo Limited (ASX:PNV) reports a 28.1% increase in H1 FY25 sales and a 23.9% rise in net profit, highlighting strong growth and expansion initiatives.
PeopleIn Limited (ASX:PPE) Reports Half-Year Financial Results
PeopleIn Limited (ASX:PPE) reports a 5% revenue decline in H1 FY25 and a significant profit drop, highlighting ongoing cost efficiencies and a positive outlook for future growth.